Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves’ orbitopathy

Abstract Purpose Patients with active, moderate-to-severe Graves’ orbitopathy require immunosuppressive treatments to reduce inflammation and morbidity. Since 2021 EUGOGO lists Mycophenolate-sodium (MPS) as first-line-treatment, which lead to a change in treatment regimens. In our center MPS was adm...

Full description

Bibliographic Details

Published in:	Thyroid Research
Main Authors:	Julius Sander, Karim Al-Ghazzawi, Nikolaos Bechrakis, Ying Chen, Inga Neumann, Anja Eckstein, Michael Oeverhaus
Format:	Article
Language:	English
Published:	BMC 2025-10-01
Subjects:	Thyroid eye disease GO TED MPS
Online Access:	https://doi.org/10.1186/s13044-025-00263-6